Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Key Takeaways

• Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.
  
• Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.
  
• Strategic partnerships and increased R&D investments introduce dependency risks and elevate costs, affecting Lexicon's financial stability, revenue potential, and market opportunities.

Catalysts

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

• Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non-opioid treatment for diabetic peripheral neuropathic pain in over two decades, which could significantly impact future revenue growth and market share.
  
• The company is developing LX9851, a first-in-class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data, which could open new revenue streams and target high-demand markets once the IND is submitted in 2025.
  
• The strategic licensing agreement with Viatris for sotagliflozin outside the U.S. and Europe provides a financial catalyst by reducing operational burden while ensuring revenue through licensing fees and potential royalties.
  
• Sotagliflozin's ongoing pivotal Phase III SONATA-HCM study could lead to expanded label indications for hypertrophic cardiomyopathy, potentially increasing market penetration and future earnings if approved.
  
• Cost reduction initiatives, such as ceasing INPEFA promotion and employee restructuring, anticipate reduced operating expenses going forward, improving net margins and potentially enhancing future profitability.

Lexicon Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Lexicon Pharmaceuticals's revenue will grow by 5.5% annually over the next 3 years.
• Analysts are not forecasting that Lexicon Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Lexicon Pharmaceuticals's profit margin will increase from -37.5% to the average US Pharmaceuticals industry of 19.7% in 3 years.
• If Lexicon Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $16.1 million (and earnings per share of $0.03) by about June 2029, up from -$26.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $24.6 million in earnings, and the most bearish expecting $-131.3 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 156.3x on those 2029 earnings, up from -34.2x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 15.1x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

• Lexicon Pharmaceuticals relies on strategic repositioning and partnerships to advance its clinical programs, which introduces dependency risks and potential delays, potentially affecting future revenues and market opportunities.
  
• The company ceased promotional efforts for INPEFA in the U.S. due to a difficult market access environment, reflecting challenges in generating significant revenue from this asset and indicating competitive pressures that may affect earnings.
  
• There was an increase in R&D expenses due to investments in clinical trials, leading to elevated operating costs which could impact net margins, especially if these programs do not yield successful outcomes or commercial products.
  
• Lexicon reported a net loss for 2024, which, despite revenue from a new licensing agreement, highlights financial challenges and the risk of not achieving profitability, impacting overall financial stability and sustainability.
  
• The ongoing need for additional pivotal trials and regulatory approvals for its pipeline suggests potential high costs and risks in drug development, which could strain financial resources and impact future earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $3.77 for Lexicon Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $1.75.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $81.9 million, earnings will come to $16.1 million, and it would be trading on a PE ratio of 156.3x, assuming you use a discount rate of 7.1%.
• Given the current share price of $2.01, the analyst price target of $3.77 is 46.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.